UK-incorporated specialty pharmaceutical company Mallinckrodt (NYSE: MNK) has agreed terms for an R&D collaboration with RNA interference (RNAi) specialist Silence Therapeutics (LON: SLN).
The companies will work together to develop and commercialize RNAi drug targets involved in the immune system that play a role in the development of inflammation.
Mallinckrodt will also make an equity investment of $5 million in Silence Therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze